Background Aprotinin is a serine protease inhibitor used to limit perioperative bleeding and reduce the need for donated blood transfusions during cardiac surgery. Randomized controlled trials of aprotinin evaluating its effect on the outcome of perioperative transfusion have been published since 1987, and systematic reviews were conducted in 1992 and 1997.
Methods A systematic search was conducted for all RCTs of aprotinin that used placebo controls or were open-label with no active control treatment. Data collected included the primary outcome, objective of each study, whether a systematic review was cited or conducted as part of the background and/or rationale for the study and the number of previously published RCTs cited. Cumulative meta-analyses were performed.
Results Sixty-four randomized, controlled trials of aprotinin were found, conducted between 1987 and 2002, reporting an endpoint of perioperative transfusion. Median trial size was 64 subjects, with a range of 20 to 1784. A cumulative meta-analysis indicated that aprotinin greatly decreased the need for perioperative transfusion, stabilizing at an odds ratio of 0.25 (p, 10 2 6) by the 12th study, published in June of 1992. The upper limit of the confidence interval never exceeded 0.65 and results were similar in all subgroups. Citation of previous RCTs was extremely low, with a median of 20% of prior trials cited. Only 7 of 44 (15%) of subsequent reports referenced the largest trial (N 1/4 1784), which was 28 times larger than the median trial size.
Conclusions This study demonstrates that investigators evaluating aprotinin were not adequately citing previous research, resulting in a large number of RCTs being conducted to address efficacy questions that prior trials had already definitively answered. Institutional review boards and journals could reduce the number of redundant trials by requiring investigators to conduct adequate searches for prior evidence and conducting systematic reviews.
Get full access to this article
View all access options for this article.
References
1.
1. Smith PK, Shah AS. The role of aprotinin in a blood-conservation program. J Cardiothorac Vasc Anesth2004; 18(4 Suppl.): S24–S28.
2.
2. Fremes SE, Wong BI, Lee E et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg1994; 58: 1580–1588.
3.
3. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Studyof Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg1997; 85: 1258–1267.
4.
4. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med1987; 317: 141–145.
5.
5. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ1994; 309: 1286–1191.
6.
6. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet1987; 2: 1289–1291.
7.
7. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (trasylol). J Thorac Cardiovasc Surg1989; 97: 364–372.
8.
8. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin – preliminary results. Thorac Cardiovasc Surg1989; 37: 89–91.
10. Locatelli A, Bertollo D, Bianchi T et al. Aprotinin in cardiosurgery: a randomized prospective study with different protocols for use. Miner Anestesiol1990; 56: 973–975.
11.
11. Dietrich W, Spannagl M, Jochum M et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology1990; 73: 1119–1126.
12.
12. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg1991; 51: 936–941.
13.
13. Boldt J, Zickmann B, Czeke A et al. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology1991; 75: 426–432.
14.
14. Deleuze P, Loisance DY, Feliz A et al. Reduction of per-and postoperative blood loss with aprotinin (Trasylol) during extracorporeal circulation. Arch Mal Coeur Vaiss1991; 84: 1797–1802.
15.
15. Gherli T, Porcu A, Padua G et al. Reducing bleeding during extracorporeal circulation interventions by high doses of aprotinin. Minerva Cardioangiol1992; 40: 121–126.
16.
16. Baele PL, Ruiz-Gomez J, Londot C et al. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg1992; 43: 103–112.
17.
17. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth1992; 6: 324–327.
18.
18. Vedrinne C, Girard C, Jegaden O et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth1992; 6: 319–323.
19.
19. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation1992; 86(5 Suppl.): II405–II409.
20.
20. Cosgrove DM, Heric B, Lytle BW et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg1992; 54: 1031–1138.
21.
21. BidstrupBP,UnderwoodSR,SapsfordRN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg1993; 105: 147–152.
22.
22. Hardy JF, Desroches J, Belisle S et al. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anesth1993; 40: 625–631.
23.
23. Isetta C, Gunness TK, Samat C et al. Antifibrinolytic treatment and homologous transfusion in cardiac surgery. Eur Heart J1993; 14: 424-424.
24.
24. Liu B, Belboul A, Radberg G et al. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg1993; 27: 149–155.
25.
25. Carrera A, Martinez MV, Garcia-Guiral M et al. Use of high doses of aprotinin in cardiac surgery. Rev Esp Anestesiol Reanim1994; 41: 13–19.
26.
26. Lemmer JHJ, Stanford W, Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg1994; 107: 543–553.
27.
27. Murkin JM, Lux J, Shannon NA et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients maintained on aspirin undergoing cardiac surgery. J Thorac Cardiovasc Surg1994; 107: 554–561.
28.
28. Bailey CR, Wielogorski AK. Randomized placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J1994; 71: 349–353.
29.
29. Bailey CR, Kelleher AA, Wielogorski AK. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg1994; 81: 969–973.
30.
30. Maccario M, Fumagalli C, Deangelis R et al. Comparison between low and high doses of aprotinin in heart surgery. Minerva Anestesiol1994; 60: 315–320.
31.
31. Rocha E, Hidalgo F, Llorens R et al. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation1994; 90: 921–927.
32.
32. Swart MJ, Gordon PC, Hayse-Gregson PB et al. High-dose aprotinin in cardiac surgery–a prospective, randomized study. Anaesth Intensive Care1994; 22: 529–533.
33.
33. Tabuchi N, Huet RC, Sturk A, Eijsman L, Wildevuur CR. Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg1994; 58: 1036–1139.
34.
34. Blauhut B, Harringer W, Bettelheim P et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardio-pulmonary bypass. J Thorac Cardiovasc Surg1994; 108: 1083–1191.
35.
35. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influenceofaprotininonearly graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg1994; 8: 651–666.
36.
36. Alvarez JM, Quiney NF, McMillan D et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth1995; 9: 29–33.
37.
37. Corbeau JJ, Monrigal JP, Jacob JP et al. Comparaison des effets de l'aprotinine et de l'acide tranexamique sur le saignement en chirurgie cardiaque. Ann Fr Anesth Réanim1995; 14: 154–161.
38.
38. Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg1995; 59: 438–442.
39.
39. Lass M, Welz A, Kochs M et al. Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardiothorac Surg1995; 9: 206–210.
40.
40. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth1995; 9: 240–244.
41.
41. Wendel HP, Heller W, Michel J et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg1995; 109: 1164–1172.
42.
42. Penta de Peppo A, Pierri MD, Scafuri A et al. Intraoperative antifibrinolysis and blood-saving techniques in Cardiac Surgery – Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J1995; 22: 231–236.
43.
43. Casas JI, Zuazu-Jausoro I, Mateo J et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. J Thorac Cardiovasc Surg1995; 110: 1107–1117.
44.
44. Dietrich W, Dilthey G, Spannagl M et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology1995; 83: 679–689.
45.
45. Levy JH, Pifarre R, Schaff HV. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation1995; 92: 2236–2244.
46.
46. Cicek S, Demirkilic U, Kuralay E, Ozal E, Tatar H. Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations. Ann Thorac Surg1996; 61: 1372–1176.
47.
47. Rodrigus IE, Vermeyen KM, De Hert SG, Amsel BJ, Walter PJ. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion1996; 11: 313–318.
48.
48. Menichetti A, Tritapepe L, Ruvolo G et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg1996; 37: 401–407.
49.
49. Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg1996; 112: 523–530.
50.
50. D'Ambra MN, Akins CW, Blackstone EH. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg1996; 112: 1081–1189.
51.
51. Lemmer JH Jr, Dilling EW, Morton JR et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Annals of Thoracic Surgery1996; 62: 1659–1167.
52.
52. Ashraf S, Tian Y, Cowan D et al. “Low-dose” aprotinin modifies hemostasis but not proinflammatory cytokine release. Ann Thorac Surg1997; 63: 68–73.
53.
53. Hardy JF, Belisle S, Couturier A, Robitaille D. Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. J Card Surg1997; 12: 15–22.
54.
54. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg1997; 114: 261–269.
55.
55. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost1997; 78: 1021–1126.
56.
56. Rossi M, Storti S, Martinelli L et al. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system. J Cardiothorac Vasc Anesth1997; 11: 835–839.
57.
57. Klein M, Keith PR, Dauben HP et al. Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin. Eur J Cardiothorac Surg1998; 14: 360–366.
58.
58. Alderman EL, Levy JH, Rich JB et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg1998; 116: 716–730.
59.
59. Basora M, Gomar C, Escolar G et al. Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin. J Cardiothorac Vasc Anesth1999; 13: 382–387.
60.
60. Ray MJ, Brown KF, Burrows CA, O'Brien MF. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass. Ann Thorac Surg1999; 68: 940–945.
61.
61. Nuttall GA, Oliver WC, Ereth MH et al. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology2000; 92: 674–682.
62.
62. Santamaria A, Mateo J, Oliver A et al. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. Haematologica2000; 85: 1277–1184.
63.
63. Tassani P, Augustin N, Barankay A, Braun SL, ZaccariaF,RichterJA. High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth2000; 14: 682–686.
64.
64. Dignan RJ, Law DW, Seah PW et al. Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations. Ann Thorac Surg2001; 71: 158–163; discussion 163–64.
65.
65. Alvarez JM, Jackson LR, Chatwin C, Smolich JJ. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg2001; 122: 457–463.
66.
66. Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation2001; 104(Suppl. 1): I265–I269.
67.
67. Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP. Aprotinin in coronary operation with cardiopulmonary bypass: does “low-dose” aprotinin inhibit the inflammatory response?Ann Thorac Surg2002; 73: 1897–1904.
68.
68. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control. Clin. Trials1996; 17:1–12.
69.
69. Freedman B. Scientific value and validity as ethical requirements for research. IRB: A Review of Human Subjects Research1987; 9: 7–10.
70.
70. Fergusson D, Blair A, Henry D et al. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Int J Technol Assess Health Care1999; 15: 717–728.
71.
71. Clarke M, Chalmers I. Discussion sections in reports of controlled trials published in general medical journals: islands in search of continents?JAMA1998; 280: 280–282.
72.
72. Gotzsche PC. Reference bias in reports of drug trials. Br Med J (Clin Res Ed)1987; 295: 654–666.
73.
73. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical?JAMA2000; 283: 2701–2211.
74.
74. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ1996; 313: 1390–1193.
75.
75. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet2001; 357: 1191–1194.
76.
76. Matthews JR. Quantification and the quest for medical uncertainty. Princeton, New Jersey: Princeton University Press; 1995.
